Clinical Trial Update: Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens [Phase 2]

View source ↗

Summary

A Phase 2 study of forodesine hydrochloride in relapsed/refractory precursor T-lymphoblastic leukemia/lymphoma was terminated; no efficacy results are provided …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Forodesine hydrochloride (forodesine hydrochloride)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Leukemia, Lymphoma | Phase 2 | Status: TERMINATED